Clinical trials: Transitional Cell Carcinoma of Urinary Bladder
Bladder Cancer Transitional Cell Carcinoma
Evaluation Of Zetiq's Novel Cell Detect Technology For Detection Of Bladder Cancer In Urine Cytology
This study includes two semi-consecutive parts: Part I Open label, controlled, Calibration part aimed to calibrate the CellDetect® device for identifying bladder cancer cells in urine samples.
- Trial name
- NCT01551342
- Where
- 7 sites in Israel
- Volunteers
- 500 people
- Sponsor
- Zetiq Technologies
Carcinoma, Transitional Cell
Neoadjuvant Atezolizumab in Localized Bladder Cancer
This phase II trial studies the best dose of atezolizumab in treating patients with bladder cancer that has not spread to other places in the body.
- Trial name
- NCT02451423
- Testing
- Atezolizumab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Lawrence Fong
Urothelial Carcinoma Bladder, Bladder Cancer
Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer
A single-arm, two-stage, open-label, phase 2 study investigating the safety and efficacy of intravesical gemcitabine/docetaxel for bacillus Calmette-Guerin (BCG)-naïve patients with non-muscle invasive bladder cancer (NMIBC).
- Trial name
- GEMDOCE (NCT04386746)
- Testing
- Gemcitabine, Docetaxel
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Urothelial Carcinoma
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
The purpose of this study is to determine the appropriate dose of AEZS-108 to treat patients with a tumor of the urinary system.
- Trial name
- NCT01234519
- Testing
- AEZS-108, AEZS-108 at MTD
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- AEterna Zentaris
Bladder Neoplasm, Neoplasm Recurrence, Local
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
This is a phase 3 randomized, active-controlled, open-label, multicenter study that will be conducted in approximately 120 investigational sites worldwide.
- Conditions
- Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ
- Trial name
- EMBARC-RF (NCT01200992)
- Testing
- EN3348, Mitomycin C
- Where
- 72 sites in United States, Canada and 4 more
- Volunteers
- 84 people
- Sponsor
- Bioniche Life Sciences Inc.
Carcinoma, Transitional Cell
Tesetaxel for Previously Treated Patients With Bladder Cancer
The intravenously administered taxanes, docetaxel and paclitaxel, alone and in combination with other chemotherapy agents are active in patients with advanced and metastatic bladder cancer, and agents of this class are a…
- Trial name
- NCT01215877
- Testing
- Tesetaxel
- Where
- 3 sites in United States, Italy
- Volunteers
- 33 people
- Sponsor
- Genta Incorporated
Urothelial Carcinoma
Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma
The purpose of this study is to see if getting chemotherapy with Gemcitabine and Cisplatin for four 21 day cycles for a total of 12 weeks can help shrink the tumor before undergoing surgery for kidney cancer.
- Trial name
- NCT01261728
- Testing
- Gemcitabine and Cisplatin
- Where
- 9 sites in United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Infiltrating Bladder Urothelial Carcinoma
Bristol Bladder Trial
26 patients with invasive primary transitional cell carcinoma of the bladder will receive 4 cycles of combination chemotherapy consisting of Cabazitaxel and Cisplatin both given intravenously on day 1 of each 3 weekly cycle prior…
- Trial name
- NCT01616875
- Testing
- Cabazitaxel + Cisplatin chemotherapy
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
Bladder Cancer, Urothelial Carcinoma
A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial
Prehabilitation refers to the process of improving a patient's functional capabilities prior to a surgical procedure with the goal of decreasing post-surgical inactivity and physical decline.
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Upper Tract Urothelial Carcinoma, Renal Pelvis and Ureter Urothelial Carcinoma
- Trial name
- NCT06040762
- Testing
- Best Practice, Exercise Intervention, App-Based Intervention
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- University of Washington
Myeloproliferative Disorder, Urothelial Carcinoma
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Gemcitabine and carboplatin are two standard chemotherapy drugs used to treat tumors of the urothelial tract. These drugs do not shrink tumors in all patients and when they do, it is generally for a limited amount of time.
- Conditions
- Myeloproliferative Disorder, Urothelial Carcinoma, Cancer
- Trial name
- NCT00588666
- Testing
- Bevacizumab, Carboplatin, Gemcitabine
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Superficial Bladder Cancer
Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
This Phase 2 study is designed to assess the efficacy and safety of INSTILADRIN (rAd-IFN with Syn3) when given intravesically to patients with high grade non-muscle invasive bladder cancer who are refractory to or have relapsed…
- Trial name
- NCT01687244
- Testing
- INSTILADRIN
- Volunteers
- 40 people
- Sponsor
- FKD Therapies Oy
Solid Tumor, Solid Carcinoma
Trop2-targeted immunoPET Imaging of Solid Tumors
This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological…
- Conditions
- Solid Tumor, Solid Carcinoma, Uroepithelial Carcinoma, Bladder Cancer
- Trial name
- NCT06851663
- Testing
- [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4
- Where
- China
- Volunteers
- 400 people
- Sponsor
- RenJi Hospital
Bladder Urothelial Carcinoma
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
The researchers are doing this study to find out whether stereotactic body radiation therapy (SBRT) in combination with immunotherapy (cemiplimab with or without fianlimab) before cystectomy is an effective and safe treatment for…
- Trial name
- NCT07414992
- Testing
- Stereotactic body radiotherapy, Cemiplimab, Cemiplimab and Fianlimab
- Where
- 7 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer, Metastatic Urothelial Carcinoma
Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)
The main goal of this clinical trial is to learn if a new targeted cancer drug called sacituzumab tirumotecan (sac-TMT) works to treat cancer while causing less nerve damage in patients with advanced urothelial carcinoma who have…
- Conditions
- Bladder Cancer, Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Peripheral Neuropathy
- Trial name
- SPARE-UC-01 (NCT07662863)
- Testing
- Sacituzumab Tirumotecan, MMAE-based ADC, Sacituzumab Tirumotecan (Observational Cohort)
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Fudan University
Urinary Bladder Neoplasms, Neoplasm Metastasis
Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
- Conditions
- Urinary Bladder Neoplasms, Neoplasm Metastasis, Carcinoma, Transitional Cell
- Trial name
- NCT07675057
- Testing
- Vepugratinib
- Sponsor
- Eli Lilly and Company
Bladder Cancer
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
This study will compare the effects, good and/or bad, of chemotherapy (Gemcitabine and Cisplatin) with or without the addition of the chemotherapy drug Cetuximab to find out which treatment is better.
- Trial name
- NCT00645593
- Testing
- Gemcitabine,, Cisplatin, Cetuximab
- Where
- 14 sites in United States
- Volunteers
- 89 people
- Sponsor
- University of Michigan Rogel Cancer Center
Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
We will combine an oral investigational vascular endothelial growth factor (VEGF inhibitor) called pazopanib which is being studied in kidney cancer will be combined with standard chemotherapy called taxol in patients with…
- Conditions
- Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)
- Trial name
- NCT01108055
- Testing
- Pazopanib (GW786034), Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Sandy Srinivas
Non-muscle Invasive Bladder Cancer, NMIBC
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
This study is being conducted to evaluate the safety and determine the recommended Phase 2 dose (RP2D) of UGN-301 (zalifrelimab) administered intravesically as monotherapy and in combination with other agents in patients with…
- Conditions
- Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer
- Trial name
- NCT05375903
- Testing
- UGN-301, UGN-201, Gemcitabine
- Where
- 13 sites in United States, Italy and 1 more
- Volunteers
- 51 people
- Sponsor
- UroGen Pharma Ltd.
Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)
Feasibility of HISA During TURBT for NMIBC
The goal of this prospective pilot study is to evaluate the safety and feasibility of using heated saline during bladder tumor surgery in patients with non-muscle invasive bladder cancer.
- Conditions
- Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy), Non-muscle Invasive Bladder Cancer (NMIBC), Non-Muscle Invasive Bladder Neoplasms
- Trial name
- NCT07817173
- Testing
- HISA
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- CAMC Health System
Bladder (Urothelial, Transitional Cell) Cancer
Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety
This is a prospective, open label, single center clinical study on the use of recombinant human adenovirus type 5 injection for bladder instillation therapy in high-risk non muscle invasive bladder urothelial carcinoma patients.
- Trial name
- REBIRTH-013 (NCT07356791)
- Testing
- Recombinant Human Adenovirus Type 5 injection
- Volunteers
- 18 people
- Sponsor
- RenJi Hospital